VIVEbiotech joins CAR-TCR Summit 2026
Peter Jähn is representing VIVEbiotech at one of the leading events for CAR-T and TCR-based therapies.
The CAR-TCR Summit 2026, organized by Hanson Wade, is now underway in Boston, bringing together companies, researchers and industry experts at the forefront of CAR-T and TCR-based therapy development.
Representing VIVEbiotech at the event, Peter Jähn is meeting with partners and key stakeholders from across the cell and gene therapy ecosystem to discuss the evolving manufacturing needs of advanced cell therapies and the growing demand for reliable lentiviral vector production.
As a specialized lentiviral vector CDMO, VIVEbiotech is showcasing its tailored solutions designed to support therapy developers throughout the entire product lifecycle, from early-stage development and clinical studies to commercial manufacturing. These discussions are particularly relevant as the sector continues to advance innovative therapies that require scalable and robust manufacturing strategies.
During the summit, Peter is engaging with attendees to exchange insights, explore collaboration opportunities and discuss how VIVEbiotech’s lentiviral vector expertise can help accelerate the development of next-generation therapies.
Taking place from September 15 to 17 at The Westin Boston Seaport District, the CAR-TCR Summit remains one of the industry’s key forums for discussing scientific progress, manufacturing innovation and the future of CAR-T and TCR-based therapies.
Those interested in connecting with VIVEbiotech during the event can schedule a meeting through the conference platform or contact directly through our website.
